Clinical trials: HEPATITIS C (HCV)
HEPATITIS C (HCV)
Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384
As part of the CE marking of a hepatitis C diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017/746).
- Trial name
- BIOPERF-HCV (NCT06623058)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- CerbaXpert
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HEPATITIS C (HCV)
Lay User Evaluation of the Panbio™ HCV Self-Test
This is a prospective, multi-centre study designed to evaluate the usability of the Panbio™ HCV Self Test, when performed by untrained lay users in an observed study setting.
- Trial name
- NCT06605573
- Testing
- Panbio™ HCV Self Test
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
HCV
National Prisons Hepatitis Education Project: Research Evaluation
The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison.
- Trial name
- HepPEd (NCT05942937)
- Testing
- Education Intervention (The HepPEd Program)
- Where
- 2 sites in Australia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C Virus (HCV) Infection
Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
This randomized controlled trial (RCT) will test the efficacy of a Community Health Worker/Registered Nurse (CHW-RN) HCV intervention for homeless individuals, many who are also drug users.
- Trial name
- NCT04513899
- Testing
- Community health worker (CHW)/ registered nurse (RN) [CHW/RN], Clinic-based Standard of Care (cbSOC) Program (control group)
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Hepatitis C Virus (HCV)
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
Hepatitis C Virus is liver disease and is a leading cause of death and morbidity with around 71 million people affected worldwide.
- Trial name
- NeoVie (NCT04366973)
- Where
- 30 sites in France
- Volunteers
- 95 people
- Sponsor
- AbbVie
Substance Use, HIV Infections
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system.
- Conditions
- Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis)
- Trial name
- NCT04134767
- Testing
- Health Linkage, Overdose Education
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- April M Young
Kidney Transplant, Hepatitis C
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
- Conditions
- Kidney Transplant, Hepatitis C, HCV
- Trial name
- NCT03801707
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Ohio State University
Hepatitis C Virus (HCV)
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- CHOICE (NCT04577482)
- Where
- 10 sites in Russia
- Volunteers
- 42 people
- Sponsor
- AbbVie
HCV Infection
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and grazoprevir [GZR] 100 mg) and EBR/GZR (varying…
- Trial name
- NCT03379506
- Testing
- EBR/GZR FDC Tablet, Grazoprevir Oral Granules, Elbasvir Oral Granules
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in…
- Trial name
- DORA (NCT03067129)
- Testing
- Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 129 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-I (NCT02219490)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 187 sites in Algeria, Australia and 25 more
- Volunteers
- 1,596 people
- Sponsor
- AbbVie
HCV Infection, Beta Thalassemia Major
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of sofosbuvir, ledipasvir and sofosbuvir metabolite (GS-331007) in HCV infected children with hematological Disorders.
- Trial name
- NCT04353986
- Testing
- Sofosbuvir and Ledipasvir
- Where
- Egypt
- Volunteers
- 24 people
- Sponsor
- Ain Shams University
Hepatitis C, People Who Inject Drugs
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care.
- Conditions
- Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
- Trial name
- NCT03214679
- Testing
- Accessible Care, Usual Care
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- City University of New York, School of Public Health
Chronic HCV Hepatitis
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients
Antiviral treatment of G1b Treatment-Naïve HCV-Infected Patients, with non- severe fibrosis, with or without insulin resistance (IR) and/or diabetes mellitus (DM) with EBR/GZR Fixed-Dose Combination for 8 Weeks.
- Trial name
- EGG-18 (NCT03496233)
- Testing
- Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
HCV Infection
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT00401947
- Testing
- ACH-0137171
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Drug Use, HCV Infection
A Community-based Intervention Among Active Drug Users in Montpellier
The study aims to assess the effectiveness of a community-based model of HCV mass screening associated with an immediate HCV treatment on the cascade of care among active drug users (DUs) in the city of Montpellier, France.
- Trial name
- ICONE (NCT04008927)
- Testing
- HCV screening, Diagnosis of hepatitis C, HCV treatment
- Where
- France
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-II (NCT02167945)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 48 sites in United States
- Volunteers
- 615 people
- Sponsor
- AbbVie
Hepatitis C Virus (HCV)
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
The objective of this study is to assess the effectiveness of the glecaprevir/pibrentasvir (GLE/PIB) regimen in adolescent participants aged 12 to <18 years of age with chronic hepatitis C (CHC) in clinical practice in the…
- Trial name
- DETI-2 (NCT04189627)
- Where
- 8 sites in Russia
- Volunteers
- 99 people
- Sponsor
- AbbVie
Hepatitis C Virus (HCV)
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
Hepatitis C Virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- EASY (NCT04352309)
- Where
- 6 sites in Russia
- Volunteers
- 99 people
- Sponsor
- AbbVie